×
About 518,278 results

Antifibrotic shows mixed results in RA-ILD
https://www.mdedge.com/chestphysician/article/258381/pulmonology/antifibrotic-shows-mixed-results-ra-ild
Pam Harrison, MDedge News

Oct 3rd, 2022 - The antifibrotic pirfenidone (Esbriet) did not change the decline in forced vital capacity percentage (FVC%) from baseline of 10% or more or the risk of death compared with placebo in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). However, the drug appeared to slow the rate of decline in lung function, a phase 2 study indicated.

The dubious value of online reviews
https://www.mdedge.com/neurology/article/258370/business-medicine/dubious-value-online-reviews
Allan M. Block, MD

Oct 3rd, 2022 - I hear other doctors talk about online reviews, both good and bad. I recently read a piece where a practice gave doctors a bonus for getting 5-star reviews, though it doesn’t say if they were penalized for getting bad reviews.

Psychiatric Risks Subside Before Neurologic Risks After COVID-19
https://www.pulmonologyadvisor.com/general-medicine/neurological-psychiatric-outcomes-covid-19-risks-last-longer/
Pulmonology Advisor

Oct 3rd, 2022 - Following COVID-19 infection, the risk for developing neurological disorders remains high after 2 years, while the risk for psychiatric disorders subsides earlier. These are the findings of a study published in Lancet Psychiatry. Researchers analyzed outcome data in a multinational, retrospective cohort study. They obtained data from the TriNetX electronic health records network between January...

APP Leaders Discuss What Keeps Them Up at Night
https://www.clinicaladvisor.com/home/topics/practice-management-information-center/national-app-week-panel/
Clinical Advisor

Oct 3rd, 2022 - Presidents from 5 advanced practice provider (APP) associations shined a light on strategies to increase the health care workforce, key bills that may change the practice landscape, how to create greater diversity among practitioners, and what keeps them up at night at an online panel discussion held in honor of the second annual National APP Week. The presidents all noted access to care issues...

Bupivacaine Now Available for Analgesia After Shoulder Surgery
https://www.rheumatologyadvisor.com/home/topics/pain-management/posimir-now-available-for-postsurgical-analgesia-following-shoulder-surgery-bupivacaine/
Rheumatology Advisor

Oct 3rd, 2022 - Posimir® (bupivacaine solution) is now available for postsurgical analgesia for up to 72 hours following arthroscopic subacromial decompression. Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered into the subacromial space under direct arthroscopic visualization. The depot product uses a sucrose-based biodegradable matrix (sucrose acetate isobu...

Monkeypox Outbreak Can Still Be Contained, Says Columbia Epidemiologist
https://www.rheumatologyadvisor.com/general-medicine/monkeypox-outbreak-contained-columbia-epidemiologist/
Rheumatology Advisor

Oct 3rd, 2022 - Health officials worldwide can still take steps to contain the monkeypox outbreak, says Dr Alissa Davis, Associate Professor at the Columbia School of Social Work, but it will require addressing the challenges of stigma, misinformation, and health inequity. “Overall case numbers of monkeypox are growing, although the number of new infections has recently been trending downward,” says Davis, an ...

Monkeypox features include mucocutaneous involvement in almost all cases
https://www.mdedge.com/dermatology/article/258366/infectious-diseases/monkeypox-features-include-mucocutaneous-involvement
Ted Bosworth

Oct 3rd, 2022 - MILAN – In the current spread of monkeypox among countries outside of Africa, this zoonotic orthopox DNA virus is sexually transmitted in more than 90% of cases, mostly among men having sex with men (MSM), and can produce severe skin and systemic symptoms but is rarely fatal, according to a breaking news presentation at the annual congress of the European Academy of Dermatology and Venereology.

Study Confirms Benefits of Lecanemab in Early Alzheimer Disease
https://www.clinicaladvisor.com/home/topics/neurology-information-center/study-confirms-benefits-of-lecanemab-in-early-alzheimer-disease/
Clinical Advisor

Oct 3rd, 2022 - Topline results were announced from a large global phase 3 confirmatory study of lecanemab for the treatment of early Alzheimer disease. Lecanemab is a humanized monoclonal antibody that works by selectively binding to, neutralizing, and eliminating soluble toxic amyloid beta aggregates. The investigational agent was by the Food and Drug Administration (FDA) in July 2022 for the treatment of mi...

Atopic Dermatitis Not Linked to VTE or JAK Inhibitors
https://www.dermatologyadvisor.com/home/topics/dermatitis/janus-kinase-inhibitors-jak-inhibitors-not-associated-with-vte-in-atopic-dermatitis/
Dermatology Advisor

Oct 3rd, 2022 - Atopic dermatitis (AD) is not associated with an increased risk for venous thromboembolism events, and neither are JAK inhibitors when used to treat AD, according to data from a systematic review and meta-analysis published in JAMA Dermatology. Investigators conducted a comprehensive literature search on electronic databases for cohort studies analyzing the association of AD with incident venou...

Children and Adolescents Present Differently With Eosinophilic Esophagitis
https://www.dermatologyadvisor.com/home/topics/dermatitis/children-and-adolescents-present-differently-with-eosinophilic-esophagitis/
Dermatology Advisor

Oct 3rd, 2022 - Young children and adolescent patients present differently with eosinophilic esophagitis (EoE), according to study results published in the Journal of Pediatric Gastroenterology and Nutrition. For the study, researchers sourced data from the European Pediatric Eosinophilic Esophagitis Registry (pEEr) registry, which was initiated in 2015 by the Eosinophilic Gastrointestinal Disorders Working Gr...

Worldwide trial seeks to revolutionize pediatric leukemia care
https://www.mdedge.com/hematology-oncology/article/258363/aml/worldwide-trial-seeks-revolutionize-pediatric-leukemia-care
Randy Dotinga

Oct 3rd, 2022 - While great strides have been made in children’s leukemia care during the past 50 years, statistics have remained grim. For acute myeloid leukemia (AML), the most common type, 5-year survival rates were just 69% for children younger than 15 between 2009 and 2015.

Positive psychiatry: An introduction
https://www.mdedge.com/psychiatry/article/258302/positive-psychiatry-introduction
Erick Messias, MD, PhD, MPH, Dilip V. Jeste, MD

Oct 3rd, 2022 - Historically, psychology and psychiatry have mostly focused on negative emotions and pathological states. However, during the last few decades, new developments in both disciplines have created novel vistas for a more comprehensive understanding of human behavior.

The accelerating societal entropy undermines mental health
https://www.mdedge.com/psychiatry/article/258304/accelerating-societal-entropy-undermines-mental-health
Henry A. Nasrallah, MD

Oct 3rd, 2022 - According to the second law of thermodynamics, it is inevitable that entropy will continue to increase over time. 1 Entropy is a measure of disorder, which can eventuate in chaos and lead to profound uncertainty, with serious psychological consequences.

More on varenicline
https://www.mdedge.com/psychiatry/article/258307/addiction-medicine
Ian R. Tofler, MBBS

Oct 3rd, 2022 - Murray et al have written a timely, thoughtful, and useful article (“Smoking cessation: Varenicline and the risk of neuropsychiatric adverse events,” Current Psychiatry, July 2022, p. 41-45) about the role of the nicotinic acetylcholine receptor partial agonist varenicline for helping patients stop smoking, which is still the main preventable cause of morbidity and premature death.

Faulty fences: Blood-brain barrier dysfunction in schizophrenia
https://www.mdedge.com/psychiatry/article/258308/schizophrenia-other-psychotic-disorders/faulty-fences-blood-brain-barrier
Delaney A. Schrenk, BS, Henry A. Nasrallah, MD

Oct 3rd, 2022 - The blood-brain barrier (BBB) is an essential barrier of closely spaced cells that regulates entry into the CNS. What passes should be highly regulated to protect the brain from potentially harmful peripheral cells or molecules from the rest of the body.

Using SNRIs to prevent migraines in patients with depression
https://www.mdedge.com/psychiatry/article/258310/depression/using-snris-prevent-migraines-patients-depression
Huda H. Ismail, PharmD, Kelly Powell, PharmD et. al.

Oct 3rd, 2022 - Ms. D, age 45, has major depressive disorder (MDD), generalized anxiety disorder (GAD), migraines, and hypertension.

Postop analgesia in Saudi Arabia and the United States: A resident’s perspective
https://www.mdedge.com/psychiatry/article/258314/addiction-medicine/postop-analgesia-saudi-arabia-and-united-states
Hashem N. Akbar, MD

Oct 3rd, 2022 - I had the opportunity to experience first-hand acute postoperative pain management in both the United States and Saudi Arabia. In this article, I discuss some of the differences in how postop pain is managed in each location, potential reasons for these differences, how they may impact patients over time, and the psychiatrist’s role in raising awareness about the hazards of overprescribing anal.

Fast Five Quiz: Monkeypox
https://www.medscape.com/viewarticle/981391

Oct 3rd, 2022 - Caused by the same family of viruses (Poxviridae) as the variola virus, monkeypox was discovered in 1958 after outbreaks occurred among research monkeys. It was first identified in humans in 1970. Before the 2022 outbreak, nearly all cases seen outside Africa were linked to the continent via travel or animal export. However, data suggest that men who have sex with men (MSM) account for a sizeab...

Standing Up for Our Patients' Rights and Our Right to Care For Them
https://www.medscape.com/viewarticle/981535

Oct 3rd, 2022 - As a family medicine physician specializing in HIV for over two decades, standing up for my patients' rights and speaking out against discrimination in healthcare have become an unavoidable and integral part of caring for my patients. When the Trump Administration in 2019 launched an initiative to end the HIV epidemic in the United States by 2030 featuring HIV preexposure prophylaxis (PrEP) as ...

FDA Approves Futibatinib (Lytgobi) for Certain Biliary Tract Cancers
https://www.medscape.com/viewarticle/981752

Oct 3rd, 2022 - The US Food and Drug Administration (FDA) has granted an accelerated approval for a new drug, futibatinib (Lytgobi), to be used for patients with a certain type of biliary tract cancer. Futibatinib was granted priority review and breakthrough designation, the agency said in its announcement. Futibatinib is indicated for use in adult patients with previously treated, unresectable, locally advanc...